DIDavod Ilbeigi

Davod Ilbeigi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Davod Ilbeigi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Protective effects of Crocin on hepatic steatosis, oxidative stress, and lipid profile in an animal model of non-alcoholic fatty liver disease

    by Hossain Rezayee, Mohammad Ali Fahmidehkar, Farimah Beheshti, Mohsen Ghoryani, Yaser Yousefpoor, Dawood Hossaini, Davod Ilbeigi

    Objective: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disorder worldwide. This study aims to investigate the effects of crocin on lipid profile, hepatic lipid accumulation, and antioxidant status in a rat model of non-alcoholic fatty liver induced by a high-fat diet. Materials and methods: Forty-two male Wistar rats were divided into six groups, each containing seven rats. Fatty liver was induced by feeding a high-fat diet for eight weeks. Subsequently, the treatment groups received intraperitoneal crocin for four weeks. The groups were then evaluated for changes in serum lipid profiles, liver function enzymes in serum, oxidative stress biomarkers and histopathological alterations in liver tissue. Results: High-fat diet feeding resulted in significant hepatic lipid accumulation, elevated serum aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase levels, increased hepatic malondialdehyde and nitrite concentrations, and impaired antioxidant enzyme activities. Histological analysis demonstrated hepatocellular steatosis, inflammatory infiltration, and hepatic structural alterations. Crocin treatment significantly attenuated lipid accumulation, normalized serum liver enzyme levels, reduced oxidative stress markers, and enhanced antioxidant enzyme activities. Histopathological evaluation further confirmed marked improvement in liver tissue morphology. Conclusion: The results of the present study demonstrate that Crocin exerts protective effects against NAFLD, highlighting its potential as a therapeutic agent for diet-induced fatty liver disease.

  • Open Access

    Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19

    by Hajar Shokri-Afra, Fatemeh Saber Jeyvan, Zeinab Barartabar, Parisa Khanicheragh, Elham Yousefi Abdolmaleki, Davod Ilbeigi, Hadis Musavi, Yalda Malekzadegan

    Sirtuin 1 (SIRT1) is a crucial regulator of cellular processes, including inflammation, metabolism, and stress responses, playing a significant role in the body′s defense mechanisms. During SARS‐CoV‐2 infection, SIRT1 plays a crucial role in modulating the immune response. This protein helps to enhance the antiviral response through deacetylating key transcription factors and regulating proinflammatory cytokines, thereby reducing the cytokine storm (an overwhelming immune response) associated with severe COVID‐19 cases. SIRT1 influences the expression of angiotensin‐converting enzyme 2 (ACE2), the primary receptor for SARS‐CoV‐2, thereby potentially mitigating viral entry and replication. Natural activators of SIRT1, such as resveratrol, have been shown to enhance its activity, offering promising avenues for therapeutic interventions aimed at bolstering the immune response during COVID‐19. Understanding the multifaceted role of SIRT1 in human defense mechanisms against SARS‐CoV‐2 could pave the way for innovative strategies to manage COVID‐19 and similar viral infections, emphasizing the importance of SIRT1 as a potential target for future therapeutic approaches.


  • Positive Correlation between Circulating Fetuin-A and Severity of Coronary Artery Disease in Men

    by Reza Afrisham, Maliheh Paknejad, Davod Ilbeigi, Sahar Sadegh-Nejadi, Sattar Gorgani-Firuzjaee, Mahmoud Vahidi

    Objective: Fetuin-A serves a dual function; its high levels are associated with metabolic syndrome, type 2 diabetes, obesity, insulin resistance, and nonalcoholic fatty liver disease, and on the other hand, it serves as a potent inhibitor of ectopic vascular calcification. Due to the opposing findings, the aim of the current study was to investigate serum fetuin-A levels in men with coronary artery disease (CAD). Methods: In the case-control study, anthropometric and biochemical parameters were determined in 83 men (43 CAD patients and 40 control subjects). At last, the serum fetuin-A levels were measured using the fetuin-A human enzyme-linked immunosorbent assay (ELISA) kit. Results: A significant difference was detected among the two groups for triglyceride and cholesterol levels (P=0.003 and P=0.002, respectively). The mean fetuin-A levels were determined 230.57 ± 63.76 and 286.35 ± 64.07 μg/ml for the control group and the CAD patients, respectively (P<0.001). Fetuin- A was significantly correlated to the severity of CAD (r 0.393, P<0.001) and associated with the risk of CAD in subjects (OR [CI] = 1. 144 [1.060-1. 235]; p = 0.001). A cut-off value of 237.4 μg/ml had good sensitivity (76.7%) and specificity (65.0%) for differentiating between two groups [area under curve (AUC) = 0.732 (CI=0.621-0.842); p < 0.001]. Conclusion: Our results indicated that fetuin-A levels were positively correlated to the severity of CAD. The findings suggest that there is a possible link between pathogenic mechanisms of atherosclerosis and fetuin-A; however, more investigations are needed in this regard.